Stämm’s Continuous Bioreactor Revolutionizes Antibody Production with Unprecedented Efficiency
SAN FRANCISCO, Jan. 17, 2025 / — Stämm, a biotechnology company focused on simplifying and scaling biomanufacturing, has announced significant advancements in its continuous bioreactor technology. Pilot studies conducted in Germany, Switzerland, and Argentina have demonstrated the potential of Stämm’s innovative bioreactor to significantly boost monoclonal antibody production, achieving a minimum of 15 times greater volumetric productivity. Projections suggest a potential increase of up to 50 times by the end of 2025.
The breakthrough was achieved using Stämm’s cutting-edge Bioprocessor, a bubble-free, continuous laminar flow bioreactor designed for both adherent and suspension cell cultures. This plug-and-play system not only eliminates the downtime typically associated with traditional fed-batch systems but also reduces production costs while maintaining product quality. The Bioprocessor consistently achieves up to 4x cellular density and enhanced specific productivity, making it a game-changer for the biomanufacturing industry.
With growing demand for biologic therapies, including biosimilars and treatments for complex diseases such as cancer, inflammation, and immune-related conditions, Stämm’s bioreactor technology is well-positioned to address critical challenges in the sector. Additionally, the system’s capabilities are extending to cell and gene therapy production, benefiting from its high surface-to-volume ratio, low shear stress, and automated features.
Stämm’s closed-system design incorporates single-use, 3D-printed cartridges that offer seamless scalability and cost-efficiency. With pilot projects successfully completed in under three months, the Bioprocessor is now ready for global deployment, particularly in underserved markets. The reactor’s superior productivity is attributed to its homogeneous environment, which ensures consistent, optimal conditions, including high gas exchange.
As the industry nears a patent cliff, Stämm is positioning itself as a key partner in advancing accessible, scalable biomanufacturing solutions. With early adoption already underway, the company’s innovative approach is set to redefine industry standards and accelerate the production of next-generation biologic therapies worldwide.
